Shandong Luoxin Pharmaceutical Group Stock Co (Shandong Luoxin Pharmaceutical Group Stock Co) Growth Rank : 0 (As of May. 06, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Shandong Luoxin Pharmaceutical Group Stock Co Growth Rank?

Shandong Luoxin Pharmaceutical Group Stock Co has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Shandong Luoxin Pharmaceutical Group Stock Co Growth Rank Related Terms

Thank you for viewing the detailed overview of Shandong Luoxin Pharmaceutical Group Stock Co's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Shandong Luoxin Pharmaceutical Group Stock Co (Shandong Luoxin Pharmaceutical Group Stock Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Luoxin Pharmaceutical Group Stock Co Ltd (OTCPK:SLUXY) » Definitions » Growth Rank

Traded in Other Exchanges

N/A

Address

Website

http://www.luoxin.cn

Shandong Luoxin Pharmaceutical Group Stock Co Ltd along with its subsidiaries is engaged in the manufacturing and selling of pharmaceutical products. It is involved in the research and development of LXI-15028, a potassium-competitive acid blocker, which is in phase III development for the treatment of reflux esophagitis and other acid-related gastrointestinal diseases; and LXI-15029, an ATP mTOR kinase inhibitor that acts as potent and selective dual inhibitors of mTORC1 and mTORC2 that controls the process of tumor formation and growth. The company mainly operates in the People's Republic of China.

Shandong Luoxin Pharmaceutical Group Stock Co (Shandong Luoxin Pharmaceutical Group Stock Co) Headlines

No Headlines